The scene at the FDA hearing was familiar. All the advisory committees have seen it play out again and again. Yesterday, it was the Pulmonary-Allergy Drug committee: The pharma doc with the convincing statement. The weeping patients. The drug likely to cost a couple thousand a month offering a slim benefit over an existing drugs. … Continue reading Should the FDA approve Vertex’s new cystic fibrosis drug?